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Humanized microbiota mice as a model of
recurrent Clostridium difficile disease
James Collins1, Jennifer M. Auchtung1, Laura Schaefer1, Kathryn A. Eaton2 and Robert A. Britton1*
Abstract
Background: Clostridium difficile disease is the leading antibiotic-associated cause of diarrhea and nosocomial
acquired infection in the western world. The per annum burden in the USA alone amounts to 250,000 cases with
14,000 ascribed deaths and medical costs in excess of a billion dollars. Novel models for the study of C. difficile
infection are therefore pertinent.
Results: Germ free C57BL/6 mice gavaged with a healthy human fecal microbiota maintained a stable “humanized”
microbiota over multiple generations when housed under specific pathogen-free (SPF) conditions. As with mice
containing a conventional microbiota, treatment with a five-antibiotic cocktail followed by a single dose of
clindamycin renders the animals susceptible to C. difficile infection (CDI). Interestingly, after recovery from the initial
CDI infection, a single intraperitoneal injection of clindamycin is sufficient to induce CDI relapse. Relapse of CDI can
be induced up to 35 days postinfection after recovery from the initial infection, and multiple episodes of relapse
can be induced.
Conclusions: This model enables the study of recurrent C. difficile disease in a host containing a human-derived
microbiota. Probiotic treatments using human-derived microbes, either prophylactic or curative, can be tested
within the model. The identification and testing of human-derived microbial communities within a humanized
microbiota mouse model may enable a higher rate of successful transfer of bacteria-based treatments from the lab
to human patients due to the microbes involved initiating from, and being adapted to, the human GI tract.
Keywords: C. difficile, Microbiota, Mouse model
Background
Clostridium difficile infection (CDI) is the principle cause
of antibiotic-associated diarrhea (AAD) and nosocomial
infection in the western world. Severe cases lead to
pseudomembranous colitis and toxic megacolon which
can require drastic surgical intervention. Recurrence oc-
curs in approximately 25 % of cases treated with metro-
nidazole or vancomycin with 12 % percent of patients
experiencing at least two recurrences and 6 % an excess
of two [1]. The per annum burden in the USA amounts
to 250,000 cases with 14,000 ascribed deaths and med-
ical costs in excess of a billion dollars [2].
Disruption of the host microbiota, whose functions
include the prevention and limitation of pathogen
colonization and growth, is the most prominent risk factor
in CDI [3]. Recently, the recapitulation of this barrier, via
fecal microbial transplantation (FMT), has shown great
promise as a treatment for recurrent CDI cases, recalci-
trant to other treatments [4]. FMT, however, has not yet
been approved by the FDA and there are safety concerns
over the use of a complex mix of bacterial, viral, and
fungal components in addition to prions and potentially
unknown biologically active substances [5].
Numerous animal [6] and in vitro [7, 8] models have
been used to study C. difficile biology, virulence factors,
and associated disease. Until recently, the golden Syrian
hamster was the most widely used model of CDI. How-
ever, hamsters rapidly succumb to disease, often becoming
moribund within 48 h, and are not suitable for studies of
recurrent disease. Therefore, researchers have shifted to-
wards the use of mouse models of CDI, and a few different
models for the study of C. difficile relapse/recurrence have
been developed. These models rely upon repeat antibiotic
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treatment with or without re-infection [9, 10] or suppres-
sion of initial infection with antibiotics [11] to achieve a re-
lapse-like state. To our knowledge, animal models to study
CDI relapse/recurrence in the presence of a human-derived
microbiota have not been described. Here, we characterize
a humanized microbiota mouse (HMbmouse) model of CDI
with the ability to induce relapse/recurrence of disease in
otherwise healthy mice by the administration of a single
dose of clindamycin. Investigation of the changes in micro-
biota that lead to susceptibility to CDI may facilitate a tar-
geted approach to identifying therapeutic microbes. The
benefit of this recurrence model is the potential to identify
human-derived microbes or microbial communities with
prophylactic or curative properties. Bacterial communities
that have coevolved within their host are likely to out-
compete those from an extraneous source within that niche
[12]. The use of an HMbmouse model colonized with
human-derived microorganisms, un-adapted to the murine
environment, overcomes this inherent problem when add-
ing back potential therapeutic human microbes [11].
Results and discussion
Humanized microbiota mice
To produce humanized microbiota mice (HMbmice), pooled
human-derived feces was administered, via gavage, to
germ free (GF) C57BL/6 mice. Microbiota was subse-
quently passed to progeny via maternal transfer and
coprophagy. To monitor and compare the fecal microbial
communities, we pyrosequence bar-coded and amplified
bacterial V3–V5 variable region 16S rDNA in fecal sam-
ples from conventional microbiota mice (CMbmice, n = 6),
HMb founder mice (GF gavaged with human feces, n = 6),
and HMb progeny (n = 16). Following clustering of
sequences (97 % similarity) and removal of singletons (op-
erational taxonomic units (OTUs) that only appear once),
371 OTUs were identified across all samples (mean 3886
reads per sample). Fifty-four OTUs were shared between
CMb/HMb mice with 137 unique to CMbmice and 180 to
HMbmice. The reduced number of unique sequences found
in CMbmice may be attributed to the smaller sample
population (n = 6 vs n = 22), limiting opportunity for spe-
cies of low abundance to be sampled. This is borne out
by comparison of alpha indices which show higher ob-
served OTUs in CMbmouse communities compared to
HMbmouse communities (mean 131.3 ± 11.4 vs 103.3 ±
18.4, p = <0.001). This could be anticipated as certain
species from the human microbiota may not survive the
transfer process or may be ill suited to the murine gastro-
intestinal tract. The reduction, albeit slight, is concordant
with data of xenomicrobiota transferred to the murine
host [13]. There was no significant difference in the
Chao1 estimator, a predictor of true richness, suggesting
that deeper sequencing would reveal more comparable
OTU numbers. CMbmouse communities possessed greater
diversity (inverse Simpson index) and evenness (Pielou) of
species (Fig. 1).
Temporal examination of the HMbmouse microbiota
revealed a significant reduction in richness (though not
biodiversity or evenness of relative abundance) in progeny
mice compared to founder mice (gavaged fecal material).
Twenty-two OTUs present in at least four of six founder
mice were absent in all progeny mice (Table 1). This may
indicate the inability of certain species to be transferred
via the parent—offspring route or an inability of these
species to remain competitive within the murine host. Fol-
lowing an initial drop between founder and progeny, alpha
diversity trended upward over generations, though not sig-
nificantly (Fig. 2).
To test for invasion of the HMbmice communities fol-
lowing multiple generations under specific pathogen-free
(SPF) conditions, 16S rDNA in fecal samples from HMbmice
(2.5 years following initial colonization of founder mice),
were sequenced on the Illumina MiSeq platform and
compared to the original pooled human fecal sample via
reciprocal BLAST search [14]. HMbMouse communities
remained remarkably immutable with ~95 % of reads
from the deep sequenced HMbmice matching sequences
identified in the original fecal sample. Reads that could
not be matched clustered into OTUs predominantly
identified as Lachnospiraceae and may represent invasive
species or those found below the level of detection in the
original fecal material.
Visualization of the beta diversity of both CMb and
HMb samples (sub-sampled to an even depth of 3224
reads per sample), using principal coordinate analysis
(PCoA) of Bray-Curtis dissimilarities followed by a boot
strapped Gap-Statistic analysis, identified three clusters:
CMbmice, gavaged founder HMbmice, and progeny HMbmice
(Fig. 3). An independent PCoA visualization of the HMbmice
groups, following removal of CMbmice, maintains the separ-
ation of gavaged founder HMbmice. No distinction was evi-
denced between the multi-generation progeny (Additional
file 1: Figure S1).
Similarities and differences between CMb/HMbmouse com-
munities at the family level are easily visualized in relative
abundance plots (Fig. 4). The largest difference is within
the Bacteroidales, which although similar in abundance dif-
fers markedly in its constituents between CMb/HMbmouse
communities. CMbmouse communities are dominated by
the Porphyromondaceae which account for almost 70 %
of all sequences compared to ~10 % in HMbmouse
communities. Within HMbmice the Bacteroidaceae ac-
count for the dominant group, comprising ~50 % of all
sequences.
In summary, HMbmice are distinguishable from CMbmice
by sequencing, are resistant to widespread invasion by
murine species, and remain stable over multiple genera-
tions when housed under SPF conditions.
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HMbMouse C. difficile infection model
Models of C. difficile infection, initially developed in the
Syrian hamster [15], have been established in conven-
tional and gnotobiotic mice as well as other animals
encompassing a broad host range [6, 16]. To produce a
robust infection model in stably colonized HMbmice, a
number of antibiotic pretreatment regimes were tested
(see “Methods” section). Only the use of a five-antibiotic
cocktail administered ad libitum in drinking water fol-
lowed by intraperitoneal (IP) injection of clindamycin re-
sulted in consistent results. To examine whether the
duration of antibiotic pretreatment affected C. difficile
disease susceptibility or severity, HMbmice were adminis-
tered the five-antibiotic cocktail for a period of 3, 4, or
5 days followed by clindamycin IP injection. Mice were
challenged 24 h later with 5 × 105 spores of either the
high toxin producing lab strain VPI10463 or a clinically
relevant NAP1/B1/027 strain CD3017 [8] (see experi-
mental outline, Fig. 5). Disease severity, measured here
by maximum weight loss (48 h post challenge), was sig-
nificantly different across antibiotic pretreatment groups
when challenged with VPI10463 (Kruskal-Wallis test, χ2 =
9:84, p = 0.007; post hoc Mann-Whitney tests with Holm
correction: 3 vs 5 days, p = 0.015; Fig. 6). Furthermore, all
animals in the 5-day antibiotic pretreatment (n = 6) reached
a moribund state requiring euthanasia, whereas animals in
the 3- (n = 6) and 4 (n = 6)-day groups recovered. Of the
mice challenged with CD3017, 6 of 18 (1/6, 3/6, and 2/6
from the 3-, 4-, and 5-dayantibiotic treatment groups, re-
spectively) reached a moribund state within 48 h. Weight
loss was higher in the groups with longer antibiotic treat-
ment; however, due to the reduced number of mice (and
therefore statistical power), the difference was not signifi-
cant (Fig. 7).
A Kruskal-Wallis test on spore count data identified a
significant difference in VPI10463 spore numbers 24 h
post challenge between antibiotic pretreatment groups
(χ2 = 12:91, p = 0.002). Post hoc Mann-Whitney tests
with Holm correction established significant differences
between groups 3 day (below level of detection) and 5
day (mean = 8.00 × 104 spores g−1 feces), p = 0.008, and
groups 4 day (mean = 2.78 × 103 spores g−1 feces) and 5
day, p = 0.023. After 48 h, only mice in the 3- and 4-day
antibiotic pretreatment groups survived with no signifi-
cant difference in spore counts (Fig. 6). Mice challenged
with CD3017 did not have a significant difference in spore
production between antibiotic pretreatment groups (Fig. 7).
However, spore levels were higher in mice that became
moribund compared to those that recovered (mean =
4.61 × 106 vs mean = 1.41 × 106 spores g−1 feces), though
Fig. 1 Comparison of α diversity between conventional and HMbmice reveals higher diversity within conventional microbiota. A Welch
two-sample t test was used to determine significance between the groups: observed OTUs, p < 0.001; Chao1 estimator (richness), p = 0.143;
inverse Simpson (biodiversity), p < 0.001; and Pielou’s evenness index, p <0.001 (evenness of relative abundance). Holm correction applied to
p values to account for multiple inference. Singletons were not removed for α analysis as they are required for the Chao1 estimator
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this difference was not statistically significant due to a
large standard deviation from the mean. Across all time
points sampled, CD3017 consistently produced more
spores than VPI10463 and continued producing detectable
spore levels for a longer period of time. CD3017 spores
were observable 14 days post challenge (mean across all
CD3017 groups day 14 = 4.42 × 103 spores g−1 feces),
whereas VPI10463 spores were undetectable by day 11.
The VPI10463 strain is known to be a poor spore former
both in vitro [17] and in vivo [18]. Conversely, increased
spore production has been proposed as a mechanism for
the spread of NAP1/B1/027 strains [19], though this is
controversial with a wide range of sporulation efficiencies
seen in vitro [20].
To examine the effect of tissue damage within the
HMbmice, histopathology was undertaken on portions of
the distal colon. Samples were scored for edema, cellular
infiltration, and epithelial damage on a scale of 0–4 for
each metric (0 being no abnormality). The sum of scores
(maximum of 12) was taken as an indicator of overall
severity. Control mice that received no antibiotic pretreat-
ment (i.e., were not susceptible to CDI) but were adminis-
tered 5 × 105 VPI10463 spores or that received antibiotic
treatment without C. difficile challenge showed minimal
pathology (n = 3, mean score 2.33 ± 0.58); mice that had
recovered from CDI presented mild disease signs (n = 3,
mean score 3.33 ± 0.58) while moribund mice had se-
vere intestinal pathology (n = 6, mean score 10.5 ± 0.55)
(Fig. 8).
Recurrent model of CDI
Recurrent CDI is a considerable complication of infec-
tion, occurring in as many as 25 % of patients. In a sep-
arate experiment, HMbmice were challenged with 5 × 104
CD3017 spores following 4 days of the five-antibiotic
pretreatment and clindamycin IP injection. The reduced
number of spores administered resulted in less weight
loss across all mice during the initial infection (n = 13,
mean % bodyweight lost 48 h post challenge = 8.16 % ±
5.9). Mice were allowed to recover from signs of disease
(weight loss, detectable spores). After recovery from ini-
tial infection, a recurrence of CDI was triggered by a
single IP injection of clindamycin. No additional spores
were administered. Groups of mice were found to be
susceptible to relapse when administered clindamycin
11, 19, or 35 days after the first C. difficile challenge
Table 1 Twenty-two OTUs were present in at least four of six founder mice that were undetected in progeny, potentially indicating
the inability of certain species to be transferred via the parent-offspring route
OTU Ave. abundancea % Abundance Order Family Genus
0010 326 10.11 Clostridiales Ruminococcaceae Unclassified
0027 115.5 3.57 Bacteroidales Prevotellaceae Paraprevotella
0047 82.3 2.55 Selenomonadales Veillonellaceae Megamonas
0050 38.3 1.19 Clostridiales Lachnospiraceae Lachnospiracea incertae sedis
0061 23.5 0.73 Bacteroidales Bacteroidaceae Bacteroides
0070 17 0.53 Clostridiales Lachnospiraceae Unclassified
0071 16.8 0.52 Clostridiales Lachnospiraceae Unclassified
0072 16.8 0.52 Clostridiales Lachnospiraceae Unclassified
0081 14.2 0.44 Bacteroidales Rikenellaceae Unclassified
0087 13.2 0.41 Clostridiales Ruminococcaceae Unclassified
0101 9.5 0.29 Bacteroidales Porphyromonadaceae Barnesiella
0103 8.3 0.26 Clostridiales Ruminococcaceae Ruminococcus
0110 7.2 0.22 Bacteroidales Unclassifed Unclassified
0118 6.3 0.2 Bacteroidales Porphyromonadaceae Barnesiella
0124 5 0.16 Clostridiales Lachnospiraceae Unclassified
0128 4.5 0.14 Clostridiales Lachnospiraceae Unclassified
0136 3.8 0.12 Erysipelotrichales Erysipelotrichaceae Erysipelotricha
0137 3.7 0.11 Clostridiales Ruminococcaceae Unclassified
0163 2.7 0.08 Fusobacteriales Fusobacteriaceae Fusobacterium
0168 2.5 0.08 Clostridiales Lachnospiraceae Unclassified
0194 1.7 0.05 Bacteroidales Porphyromonadaceae Barnesiella
0235 1 0.03 Erysipelotrichales Erysipelotrichaceae Erysipelotrichace incertae sedis
aAverage abundance of OTU in founder mice
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Fig. 2 HMbMice progeny have a lower α diversity than gavaged founder mice. Pairwise t tests with pooled SD and Holm correction for multiple
tests were used to determine significant differences. Singletons were not removed for α analysis as they are required for correct calculation of the
Chao1 estimator. Descendant HMbmouse samples were taken from mice aged 6–10 weeks from offspring of founder mice at 4, 9, and 11 months
post initial gavage of fecal material
Fig. 3 Clustering of conventional and humanized mouse microbiota based upon principal coordinates analysis (PCoA) of Bray-Curtis dissimilarities.
A clear distinction can be visualized along axis 1, accounting for 74.6 % dissimilarity between conventional mouse microbiota (blue, n = 6) and
humanized mouse microbiota (green, founder mice 3 weeks post gavage n = 6. Orange, offspring of gavaged mice with microbiota derived by
maternal transfer, n = 16). A goodness of clustering measure, the “gap” statistic independently identified three clusters belonging to CMbmice,
gavaged founder HMbmice, and their offspring
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(Fig. 9a–c). HMbMouse weight immediately prior to re-
lapse was normalized to 100 %. Weight loss did not
significantly differ between groups upon relapse, regard-
less of when triggered (11–35 days post initial challenge,
combined weight loss 48 h after relapse: n = 13, 9.87 % ±
3.43). Following an initial clindamycin induced relapse
(11 days postinfection), a further CDI episode could be
provoked (41 days post the initial infection and 30 days
after the first relapse) upon an additional clindamycin
injection (n = 5, mean weight loss 48 h post second
relapse 4.97 % ± 2.11) (Fig. 9c).
C. difficile spores in feces were below the level of
detection at the time of relapse induction (as determined
by plating). One possibility is that spores adhered to the
coat of HMbmice (cages were changed with sterile re-
placements weekly), triggering relapse upon ingestion in
post clindamycin-susceptible animals. Another hypoth-
esis is that vegetative cells or spores remained associ-
ated, at low levels, within the murine gastrointestinal
(GI) tract. Within 24 h of triggering CDI relapse, spores
were detected at levels ≥107 g−1 feces, where they
remained for ~5 days before waning to undetectable
levels (Fig. 9). This rapid increase suggests that vegeta-
tive cells may already be present within the intestine,
allowing for rapid growth and spore production when
conditions permit. An association of C. difficile and the
gut mucosa/epithelium has been observed previously in
both animal [21] and in vitro experiments [22].
Effect of antibiotics and C. difficile infection on the
HMbmouse microbiota
The use of antibiotics can significantly reduce or ablate
sensitive species while simultaneously allowing resistant
opportunists to bloom [23]. To examine this effect in
HMbmice, fecal samples were sequenced by Illumina
Fig. 4 Relative abundance of major bacterial orders in the gut microbiota from CMb and HMb mice. Data are average relative abundances of
OTUs assigned at the family level of sequenced communities from CMbmice, n = 6, founder HMbmice, n = 6; HMboffspring at 4 months, n = 4;
HMboffspring at 9 months, n = 6; HMboffspring at 11 months, n = 6
Fig. 5 Experiment design. A five-antibiotic cocktail consisting of
kanamycin (0.4 mg ml−1), gentamicin (0.035 mg ml−1), colistin
(850 U ml−1), metronidazole (0.215 mg ml−1), and vancomycin
(0.045 mg ml−1)) was administered ad libitum in drinking water for
3, 4, or 5 days. Antibiotic water was changed to sterile antibiotic free
water and 24 h later mice were administered an intra-peritoneal
injection of clindamycin (10 mg kg−1). Twenty-four hours post
clindamycin IP, mice are challenged with C. difficile spores by oral
gavage and monitored for signs of disease. Recurrent CDI is induced
by administration of a further clindamycin injection (10 mg kg−1)
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MiSeq (average reads per sample 35,505, sub-sampled to
an even depth of 23,057) from three time points: base
composition, prior to antibiotic insult; post-antibiotics,
immediately following the five-antibiotic cocktail and clin-
damycin IP injection; recovered, following challenge with
C. difficile and subsequent recovery from CDI, 14–17 days
post cessation of antibiotics.
Comparison of microbial community structures for
changes in abundance enables identification of bacteria
that potentially facilitate susceptibility/increased severity
or resistance/amelioration of C. difficile disease. Principal
coordinate analysis of Bray-Curtis dissimilarity of commu-
nities prior to antibiotics (n = 38), following 3, 4, or 5 days
of antibiotics (n = 36), and ensuing recovery from C. diffi-
cile infection (n = 31) was undertaken. Examination of
communities from the antibiotic time courses revealed
little obvious difference in community structure regardless
of duration. Furthermore, communities that recovered
from the antibiotic assault (14–17 days post-antibiotic
cessation) and C. difficile challenge look remarkably simi-
lar to unperturbed, pre-antibiotic, communities (Fig. 10)
despite their susceptibility to clindamycin-induced CDI
relapse.
Pre- vs post-antibiotic treated microbiota
To examine the effect of antibiotics on the HMbmouse
microbiome in more detail, data were subset into pre-anti-
biotic and immediately post-antibiotic cessation samples.
Differentially abundant OTUs between the two groups
were detected using negative binomial generalized linear
models with DESeq2 in R. Originally designed to detect
differentially abundant gene expression from RNA-Seq
data, this package has been shown to work well with 16S
sequencing count data [24]. p values were corrected for
multiple inference using the Benjamini-Hochberg false
discovery rate (FDR) procedure and a strict adjusted alpha
cutoff value of 0.01 set as criteria for inclusion. Two hun-
dred and eighteen OTUs were found to have significantly
different abundances. One hundred and ninety-eight
OTUs decreased while 20 OTUs increased post-antibiotic
use (see Additional file 2: Table S1). Of those OTUs that
decreased, 44.4 % belonged to the Lachnospiraceae, 16.7 %
Fig. 6 Mean relative mouse weights and spore counts after C. difficile VPI10463 challenge. Mice were administered a five-antibiotic cocktail in
drinking water ad libitum for 3, 4, or 5 days followed by an IP injection of clindamycin (10 mg kg−1). Twenty-four hours after IP injection, mice
were challenged with the high toxin producing strain VPI10463 (n = 6 for each group). Antibiotic and C. difficile control groups showed no signs
of weight loss or disease (data not shown). Fecal samples were homogenized in 500 μl PBS and heated to 65 °C for 30 min to kill vegetative cells.
Samples were serially diluted and plated in replicate on TCCFA plates to enumerate C. difficile spore numbers. No spores were detected in the
negative control group or the no antibiotics control group even with 106 spores administered by gavage (not shown). Shaded area and error bars
indicate standard deviation from mean. *6/6 mice became moribund. ND spores non-detectable
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Fig. 7 Mean relative mouse weights and spore counts after C. difficile CD3017 challenge. Mice were administered a five-antibiotic cocktail in
drinking water ad libitum for 3, 4, or 5 days followed by an IP injection of clindamycin (10 mg kg−1). Twenty-four hours after IP injection mice
were challenged with the clinical NAP1/B1/027 ribotype strain, CD3017 (n = 6 for each group). Fecal samples were homogenized in 500 μl PBS
and heated to 65 °C for 30 min to kill vegetative cells. Samples were serially diluted and plated in replicate on TCCFA plates to enumerate C. difficile
spore numbers. Shaded area and error bars indicate standard deviation from mean. *1/6, 3/6, and 2/6 mice became moribund in the 3-, 4-, and 5-day
Abx groups, respectively. ND spores non-detectable
Fig. 8 Histopathology of disease. Histological sections of distal colon were scored blindly by an independent researcher. Three criteria, edema,
cellular infiltration, and epithelial damage, were individually scored from 0–4 (a score of 0 indicates no pathology), and the three values summed
to give a disease severity score
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Fig. 9 HMbMouse model of recurrent CDI. Mice were administered a five-antibiotic cocktail in drinking water ad libitum for 4 days followed by an
IP injection of clindamycin (10 mg kg−1). Twenty-four hours after IP injection, mice were challenged with the clinical NAP1/B1/027 ribotype strain,
CD3017 (a: n = 5, b: n = 4, c: n = 4). Relapse was induced by further IP injection of clindamycin (10 mg kg−1). Shaded area and error bars indicate
standard deviation from mean. Star = clindamycin-induced relapse. ND spores non-detectable. C. difficile Spore numbers were enumerated by
homogenizing fecal samples in 500 μl PBS and heating to 65 °C for 30 min to kill vegetative cells followed by serial dilution and plating in
replicate on TCCFA plates
Fig. 10 Clustering of HMbmice communities: pre-antibiotics, post-antibiotics, and following recovery from C. difficile infection based upon principal
coordinates analysis (PCoA) of Bray-Curtis dissimilarities. HMbMouse communities that have undergone 3, 4, or 5 days of antibiotic treatment
(3 day, 4 day, 5 day) separate clearly from pre-antibiotic or recovered groups, though do not form distinct clusters of their own as determined by
the gap statistic. Communities that have recovered from antibiotic assault only (5 day recov B) and antibiotic assault plus C. difficile invasion
(3 day recov, 4 day recov, 5 day recov) return to a pre-antibiotic-like state as evidenced by the close grouping of these communities
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to the Ruminococcaceae, 9.1 % Bacteroidaceae, and the
remaining 29.8 % were split across 12 family groups or un-
classified. This wide-ranging reduction of taxa can be ex-
plained by the fact that the five-antibiotic cocktail
possesses a broad spectrum of antimicrobial activity, tar-
geting both Gram positive and negative species via mul-
tiple modes of action.
Proposed mechanisms of colonization resistance in
respect to C. difficile include competition for sparse re-
sources within a niche; microbially produced short-chain
fatty acids, specifically butyrate; and the conversion of
primary bile acids into secondary acids via 7α-dehydroxy-
lating bacteria. Overall, 69.7 % of the OTUs significantly
decreased by antibiotic treatment belonged to the Clos-
tridia, potentially freeing a niche for C. difficile to exploit.
Butyrate possesses anti-inflammatory properties, provides
the preferred energy source in colonocytes, and can
directly inhibit C. difficile growth in vitro [25]. Members
of the Lachnospiraceae and Ruminococcaceae are known
to be primary butyrate producers [26], so their significant
reduction likely leads to reduced butyrate production, in-
creasing susceptibility to CDI. Primary bile acids, such as
taurocholic acid, are known to induce C. difficile germin-
ation while secondary bile acids can exert inhibitory ef-
fects on germination or kill vegetative cells [27]. The
majority of known bile acid 7α-dehydroxylating bacteria
belong to Clostridium cluster XIVa [28], of which six
OTUs were significantly reduced following antibiotics.
Removal of 7α-dehydroxylating bacteria can alter the pro-
portions of primary and secondary bile acids, switching
the environment from inhibitory to stimulatory in respect
to C. difficile spore germination [29, 30].
Of the OTUs that increased, the largest increase (base
mean = 159, log2 fold change = 8.48) belonged to an
Enterococcaceae which are known to bloom in humans
undergoing certain antibiotic treatments [31, 32] and
have been shown to correlate positively with CDI [33].
These blooms may be incidental or may have a synergis-
tic effect on disease severity.
Microbiota in moribund vs recovered mice
Indicator species analysis can be applied to identify OTUs
that differ in their occurrence or relative abundances
between groups. The fidelity (probability an OTU occurs
within a group) and specificity (the proportion of groups
that contain an OTU) of all OTUs were calculated and
the statistical significance of their associations inferred by
permutation followed by Benjamini-Hochberg correction
for multiple inference [34]. An OTU is highly characteris-
tic of a group if it is significantly more likely to occur in
that group than in another or is considerably more abun-
dant in that group. Mice challenged with C. difficile
following antibiotic pretreatment can be split into two
groups: “alive” (those that recover) and “dead” (those that
become moribund). By carrying out indicator species ana-
lysis on these groups, it is possible to correlate OTUs to
outcomes that, with further empirical testing, may be
shown to reduce or increase the effect of CDI. Four OTUs
were associated with mice that survived and 13 with mori-
bund animals (Table 2, alpha cutoff for inclusion = 0.1). Of
the four OTUs indicative of mice that survived, two stood
out: OTU44, classified to the genus level as Clostridium
cluster XIVa, a group associated with butyrate production
[35]; and OTU91, a Blautia whose sequence matched
Blautia hansenii by BLAST search and is annotated to
possess bile-acid 7α-dehydroxylase activity. Recently,
Blautia hansenii was predicted to have a negative, inhibi-
tory, interaction with C. difficile in both humans and
mouse models [36]. Furthermore, the addition of a bacter-
ial species, Clostridium scindens, containing bile-acid 7α-
dehydroxylase activity was shown to ameliorate CDI in a
mouse model [36]. No obvious associations could be made
for OTUs indicative to moribund animals, in part because
eight of the 13 were unclassified at the family level. Those
that were identified comprised Parabacteroides (2), Para-
sutterella, Clostridium sensu stricto, and an unclassified
Ruminococcaceae. The isolation and testing of these
strains for their protective, in the first instance, or syner-
gistic deleterious effect, in the latter, may provide further
insight into the treatment or progression of CDI.
Recovery of HMbmouse microbiota following antibiotic
treatment and C. difficile infection
It has been proposed that just a single course of antibiotic
use can lead to long-term shifts in the microbiota [37].
Visualization of family level abundances reveals similarity
between the untreated and the recovered groups suggest-
ing that HMbmice communities return to their stable state
within 14–17 days of antibiotic cessation (Fig. 11). To
examine the effect of antibiotic treatment followed by CDI
in HMbmice communities, the data were subset into pre-
antibiotic (n = 38) and recovered (n = 25) samples (taken
14–17 days post-antibiotic cessation and C. difficile chal-
lenge); samples that received antibiotics but were not
challenged with C. difficile were excluded from analysis.
Forty-two OTUs showed a significant difference, consid-
erably less than the 218 in the pre vs post antibiotic
treatment groups, including a decrease in 19 OTUs and
an increase in 23 OTUs in the recovered communities
compared to the pre-antibiotic-treated communities
(Additional file 3: Table S2). Eighteen of the 19 OTUs
with reduced abundance were also diminished immedi-
ately following antibiotic cessation indicating that they
had not yet recovered, though in all cases were trending
back towards their base abundance (i.e., the log2 fold
change was closer to zero). Just one OTU, classifying as
a Clostridium cluster XlVb, had reduced abundance in
the recovered samples that was not seen to be reduced
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immediately following antibiotic cessation. Of the 23
OTUs with increased abundance, 14 were OTUs that have
been significantly reduced by antibiotics and had re-
bounded during recovery to a higher than baseline state.
Of the remaining OTUs, one, present in 18 of 25 recov-
ered samples, was C. difficile as determined by BLAST
search. The presence of C. difficile, albeit at low levels (0–
24 reads in non-sub-sampled/normalized samples or 0–
0.07 % of reads, median 0.003 %), is evidence that it is not
always cleared following recovery from disease, providing
a potential reservoir for relapse when conditions permit.
The remaining eight OTUs were diversely composed of
Lachnospiraceae, Bacteroidaceae, Streptococcaceae, Clos-
tridiaceae, and Verrucomicrobiaceae. Examination of the
alpha metrics associated with pre-antibiotic and recovered
samples show a significant increase in estimated richness
while evenness is reduced in recovered samples, though
the difference in both cases is slight. There was no dispar-
ity in diversity between the two groups (Table 3). Taken
together, it could be concluded that HMbmice communi-
ties would return to their base constitution given enough
time following antibiotic insult.
Conclusion
Fecal microbial transplantation (FMT) as a treatment for
C. difficile disease is not a contemporary idea, having
been reported in scientific literature for over 50 years
[38]. Recently, the use of FMT for the treatment of
recurrent CDI has burgeoned with a reported efficacy of
>90 % [4]. Despite this, CDI remains the most prevalent
nosocomal disease in the developed world. There are
tangible risks associated with administering an unknown
microbiota to a patient. Increased use of FMT will bring
with it a heightened likelihood of seeing complications
such as infection, allergic response, or long-term unsus-
pected sequelae such as weight gain [39]. An alternative
to using the mélange of bacteria, fungi, and virons
present in FMT samples is to create a defined cocktail of
well characterized, sequenced, bacteria that is shown to
be efficacious in its treatment or prevention of CDI. This
approach has been successfully applied in conventional
mouse models using indigenous murine microbes [11]
and to ameliorate disease using specific human derived
microbiota [36].
The use of HMbmice as a model of both CDI and re-
current CDI in combination with sequencing technology
and advanced bacterial isolation techniques provides a
resource for the identification of beneficial microbes and




Germ-free C57BL/6 mice were administered, via oral
gavage, a human-derived fecal microbiota from a pooled
fecal slurry of 12 healthy adults as described in Robinson
et al. [8] and classified as HMbmice. HMbmice derived by
gavage were housed and bred in gnotobiotic isolators.
Table 2 Differentially abundant OTUs in moribund vs recovered HMbmice communities
OTU Association padj Order Family Genus
00091 Alive 0.065 Clostridiales Lachnospiraceae Blautia
00069 Alive 0.0041 Clostridiales Lachnospiraceae Unclassified
00044 Alive 0.0313 Clostridiales Lachnospiraceae Clostridium XIVa
00106 Alive 0.0611 Bacteroidales Unclassified Unclassified
00172 Dead 0.0351 Unclassified Unclassified Unclassified
00377 Dead 0.0134 Clostridiales Unclassified Unclassified
00127 Dead 0.0279 Unclassified Unclassified Unclassified
00257 Dead 0.0282 Unclassified Unclassified Unclassified
00153 Dead 0.0406 Clostridiales Unclassified Unclassified
00201 Dead 0.0392 Bacteroidales Porphyromonadaceae Parabacteroides
00189 Dead 0.0286 Bacteroidales Porphyromonadaceae Parabacteroides
00250 Dead 0.0566 Bacteroidales Unclassified Unclassified
00441 Dead 0.061 Burkholderiales Sutterellaceae Parasutterella
00769 Dead 0.0558 Clostridiales Clostridiaceae Clostridium sensu stricto
00195 Dead 0.0407 Clostridiales Unclassified Unclassified
00064 Dead 0.0755 Clostridiales Ruminococcaceae Unclassified
01786 Dead 0.0536 Unclassified Unclassified Unclassified
Mice challenged with 5 × 106 CD3017 spores following antibiotic pretreatment were parsed into two groups: moribund (those mice that required euthanasia,
n = 4) and recovered (mice that survived CDI, n = 9) with the differential abundances of OTUs immediately prior to C. difficile infection analyzed using DESeq2 in R.
p values were corrected using the Benjamini-Hochberg false discovery rate (FDR) procedure and a corrected alpha value cutoff of <0.1 used for inclusion
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Progeny and descendants of the founder HMbmice ac-
quired their microbiota via maternal transfer and were
maintained under SPF conditions. To limit the introduc-
tion of invasive species, gloves were changed between
handling conventional microbiota mice (CMbmice) and all
chow, water, and bedding autoclaved prior to use. All des-
cendant HMbmouse samples were taken from mice aged
6–10 weeks from offspring of founder mice at time points
4, 9, and 11 months post initial gavage of fecal material. A
separate sample was taken from mice 2.5 years, and mul-
tiple generations, out for comparison to the original start-
ing fecal material. The animal use protocol was approved
by the Animal Ethics Committee of Baylor College of
Medicine (Protocol no. AN-6675).
Microbiome analysis
Mouse fecal samples were collected in sterile microfuge
tubes and stored at −80 °C until needed. DNA was ex-
tracted by bead beating and modified extraction and
cleanup with the Qiagen DNEasy Tissue Kit as described
previously [8]. For temporal analysis of the HMbmice, the
V3–V5 region of the 16S rRNA gene was amplified by
PCR using the 357F/962R primers with unique barcodes
designed by the Human Microbiome Project [40] and
sequenced using a 454 GS Junior (Roche Diagnostics).
Analysis of microbial communities following antibiotic
administration and C. difficile challenge experiments was
carried out by amplifying the V4 region of the 16S rRNA
gene with primers F515/R806, using a dual indexing
Table 3 Comparison of alpha measurements between pre-antibiotic and recovered HMbmouse communities
Observed Chao1 Inverse Simpson Pielou’s evenness
Group N Mean SD P Mean SD P Mean SD P Mean SD P
Pre Abx 38 191.9 26 0.051 265.7 57.7 0.006 12.6 3.3 0.631 0.612 0.03 0.009
Recov 25 205.7 27.2 315.3 71.6 12.2 2.8 0.59 0.03
SD standard deviation. P student’s t test with Holm adjustment for multiple comparisons
Fig. 11 Relative abundance of major bacterial orders broken down at family level in the gut microbiota from HMbmice. Data are average relative
abundances of OTUs assigned at the family level of sequenced communities from: 0, pre-antibiotics (n = 38); 3, 3 day Abx (n = 8); 4, 4 day Abx
(n = 11); 5, 5 day Abx (n = 17), R3, 3 day Abx group 14–17 days postinfection (n = 12); R4, 4 day Abx group 14–17 days postinfection (n = 9); R5,
4 day Abx group 14–17 days postinfection (n = 4); R5b, 5 day Abx group 14–17 days post cessation of antibiotics—no C. difficile challenge (n = 6)
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approach (4 forward primer; 96 reverse primer) and sub-
sequent sequencing by Illumina MiSeq. The 96-indexed
R806 primers used were previously described in Caparaso
et al. [41] (806rbc0–806rbc96). The indexed F515 primers
were essentially as described in Kozich et al. [42], except
that we generated four barcodes that balanced the nucleo-
tide composition at each position (atcgatgg, tcacgaca,
ggtatctc, and cagtcgat) in place of those described in
Kozich et al.
PCR reactions were carried out in triplicate. Each reac-
tion contained 4 μl of diluted template, 1X Phusion High-
Fidelity Buffer (New England Biolabs), 200 μM dNTPs
(Promega or Invitrogen), 10 nM primers, 0.2 units of Phu-
sion DNA Polymerase (New England Biolabs), and PCR
grade water to a final volume of 20 μl. The amplification
cycle consisted of an initial denaturation at 98 °C for 30 s,
followed by 30 cycles of 10 s at 98 °C, 20 s at 51 °C, and
1 min at 72 °C. Replicates were pooled and cleaned using
AMPure beads as previously described [8]. DNA sample
concentrations were determined with Quant-iT (Life
Technologies) and pooled at equimolar ratios. Prior to se-
quencing, the quality of pooled DNA was assessed by ana-
lysis on a Bioanalyzer High Sensitivity DNA Kit (Agilent).
Sequence data analysis
Sequence data were processed using platform-specific
(454/MiSeq) pipelines in Mothur v.1.34.3 [43] based
upon published SOPs [44, 45]. Alignment was achieved
using the Silva 16S rRNA gene reference database.
Chimeric sequences and any classifying as chloroplast,
mitochondria, Archaea, or Eukaryota were removed after
identification by the Mothur implementation of uchime or
mothur-formatted ribosomal database project (version 9)
classifier, respectively. Sequences were clustered by the
average-neighbor method into operational taxonomic
units (OTUs) of ≥97 % sequence identity. Analysis of
OTU data were performed in R [46] using the phyloseq
[47], DESeq2 [48], and indicspecies [49] packages. Se-
quence data are available via the Sequence Read Archive
(SRA) accession numbers SRP061089 and SRP061088.
Alpha diversity
To examine differences in community alpha measure-
ments, several metrics were compared. Richness: both a
count of observed OTUs and an estimate of true species
richness of a sample with Chao1. Evenness: a measure of
how similarly taxa are represented in abundance. Pielou’s
evenness index ranges from zero to one with low values
indicating uneven communities in which one or a few
taxa are highly represented and high values indicating
communities with more even representation among taxa.
Diversity: the quantification of both richness and even-
ness. The inverse Simpson index values are higher when
either many taxa are present, or when they are more
similar in abundance.




Pielou0s evenness : J ¼ −Σ
Sobs





where D ¼ Σ
Sobs
i−1 ni ni−1ð Þ
N N−1ð Þ
Sobs = the number of species in the sample, F1 = the
number of singletons (single occurrence within a sam-
ple) and F2 = the number of doubletons.
pi = proportion of Sobs made up of the ith species.
ni = the number of individuals in the ith OTU and N =
the total number of individuals in the community.
Beta diversity
The Bray-Curtis dissimilarity matrix was used to de-
scribe differences in microbial community structure. Pat-
terns of similarity among the different HMb/CMbmouse
fecal communities were examined using principal coordi-
nates analysis (PCoA). Robustness of results was tested by
recomputing output using alternative dissimilarity mea-
sures (Jaccard, thetayc) and ordinations (non-metric multi-
dimensional scaling (NMDS)). No significant changes were
observed (data not shown).
Spore preparation and enumeration
Individual C. difficile colonies were picked into pre-
reduced BHIS media and propagated anaerobically at 37 °C
overnight. Spores were cultivated by spread plating over-
night BHIS cultures onto BHIS medium and incubating
anaerobically at 37 °C for 5 days. Spores were scraped
from plates, resuspended in sterile water, and heated to
65 °C for 30 min to kill vegetative cells. Viable spores were
enumerated by plating serial dilutions on BHIS plates
supplemented with 0.1 % taurocholic acid. Spore prepara-
tions were diluted in sterile water to a final concentration
of 5 × 106 spores ml−1 and maintained at 4 °C until used.
To enumerate C. difficile spores from HMbmouse feces,
fecal pellets were weighed, homogenized in 500 μl sterile
water, and incubated at 65 °C for 30 min to kill vegetative
cells. Following heat killing, spores were serially diluted
and spot plated in duplicate onto selective TCCFA plates
containing 0.1 % taurocholic acid.
Establishment of robust C. difficile infection model in
HMbmice
To produce a robust infection model in HMbmice, a num-
ber of antibiotic pretreatment regimes, known to work
well in CMbmice, were tested including the following: cefo-
perazone (0.5 mg ml−1) in sterile drinking water for
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10 days [50] and clindamycin (0.25 mg ml−1) in drinking
water for 7 days [51]. However, only the use of a five-
antibiotic cocktail developed by Chen et al. [9] pro-
duced reproducible results in HMbmice. HMbMice were
administered kanamycin (0.4 mg ml−1), gentamicin
(0.035 mg ml−1), colistin (850 U ml−1), metronidazole
(0.215 mg ml−1), and vancomycin (0.045 mg ml−1) ad
libitum in drinking water for 3–5 days followed 24 h
later by IP injection of clindamycin (10 mg kg−1).
Twenty-four hours post IP injection, mice were chal-
lenged, via oral gavage, with 5 × 105 spores of either the
high toxin producing strain VPI10463 or the clinically
relevant NAP1/B1/027 ribotype strain CD3017. Symp-
toms were similar to those observed in humans: diar-
rhea, weight loss, and histologic damage.
CDI recurrence/relapse
HMbMice were administered the five-antibiotic cocktail
for 4 days ad libitum in drinking water followed by IP
clindamycin injection. Twenty-four hours later, mice
were challenged with 5 × 104 CD3017 spores (tenfold
lower compared to prior experiments was used to
minimize mouse mortality while maintaining CDI symp-
toms). Following recovery from initial CDI, relapse was
triggered by administering a further single dose of clin-
damycin (10 mg kg−1) up to 4 weeks post recovery from
initial infection.
Histopathology
Histological sections of distal colon were scored blindly
by an independent researcher utilizing the scoring
system outlined in Theriot et al. [50]. Briefly, three cri-
teria: edema, cellular infiltration, and epithelial damage
were individually scored from 0–4 (where a score of 0
indicates no pathology) and the values summed to give
an overall disease severity score.
Additional files
Additional file 1: Clustering of humanized mouse microbiota based
upon principal coordinates analysis (PCoA) of Bray-Curtis
dissimilarities. A distinction along axis 1, accounting for 41.3 %
dissimilarity, can be visualized between humanized mouse microbiota
founder mice and their offspring. (PNG 120 kb)
Additional file 2: Differentially abundant OTUs in pre-antibiotic vs
post-antibiotic HMbmice communities. Two hundred and eighteen
OTUs were significantly affected by antibiotic treatment. One hundred
and ninety eight were significantly reduced while 20 OTUs were able to
resist the antibiotic insult and increase in abundance. Significant
differential abundances of OTUs were analyzed using DESeq2 in R.
p values were corrected using the Benjamini-Hochberg false discovery
rate (FDR) procedure with a corrected alpha value cutoff of 0.01.
(PNG 120 kb)
Additional file 3: Differentially abundant OTUs in pre-antibiotic vs
recovered HMbmice communities. The ability of HMbmouse microbiota
to return to a “normal” state following recovery from antibiotic insult and
CDI was tested by comparing the two groups: pretreatment (no
antibiotics, n = 38) and recovered (14–17 days post antibiotic cessation
and CDI, n = 25). Significant differential abundances of OTUs were
analyzed using DESeq2 in R. p values were corrected using the
Benjamini-Hochberg false discovery rate (FDR) procedure with a
corrected alpha value cutoff of 0.01. (PDF 260 kb)
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